Lungs News and Research

RSS

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it is initiating a multicenter Phase 2b clinical trial with its oncology drug candidate tamibarotene in combination with chemotherapeutical agents for the treatment of patients with advanced non-small-cell lung cancer (NSCLC).

2 Dec 2010

American-style diet plays a vital role in prostate cancer, researchers say

Elevated fat and cholesterol levels found in a typical American-style diet plays an important role in the growth and spread of prostate cancer, say researchers at Thomas Jefferson University's Kimmel Cancer Center.

2 Dec 2010

Noncancerous cells from primary site appear to facilitate tumor growth: Study

The process of metastasis requires that cancer cells traveling from a primary tumor find a hospitable environment in which to implant themselves and grow. A new study from Massachusetts General Hospital (MGH) Cancer Center researchers finds that circulating tumor cells prepare this environment by bringing along from their original site noncancerous cells that support tumor growth. The report has been published online in PNAS Early Edition.

1 Dec 2010

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010

IDEA clinical study seeks to promote weight loss among young adults

Obesity It's a national epidemic and on the rise in young adults. Using technology to combat this problem, the University of Pittsburgh Physical Activity and Weight Management Research Center will offer the IDEA (Innovative Approaches to Diet, Exercise, and Activity) study, one of seven clinical trials to be funded by the National Institutes of Health's (NIH) National Heart, Lung, and Blood Institute.

1 Dec 2010

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

1 Dec 2010

Common sleep complaints predict development of metabolic syndrome: Study

A study in the Dec. 1 issue of the journal SLEEP found that loud snoring and two common insomnia symptoms difficulty falling asleep and unrefreshing sleep each significantly predicted the development of the metabolic syndrome. The study emphasizes the importance of screening for common sleep complaints in routine clinical practice.

1 Dec 2010

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

The National Comprehensive Cancer Network has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clinical activity of axitinib in various tumor types.

1 Dec 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Canadians at increased risk for flu complications not aware of all the facts

It starts with a headache, chills or that all-over-achy feeling. It comes on quickly, yet too many Canadians ignore the rapid onset of flu symptoms. But for the millions of Canadians at increased risk for developing serious complications from the flu, including people 65 and older, pregnant women and those with chronic medical conditions like chronic obstructive pulmonary disease (COPD), asthma, heart disease and diabetes, this 'laissez faire' attitude could be putting their health in jeopardy.

30 Nov 2010

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the initiation of a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.

30 Nov 2010

APP to launch Topotecan for Injection following FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Topotecan for Injection, and plans to launch immediately.

30 Nov 2010

People with OSA are prone to develop atherosclerosis: Study

People with obstructive sleep apnea (OSA), a sleep disorder associated with obesity, have more non-calcified or "bad" plaque in their coronary arteries, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

New chest X-ray technology enhances lung nodule detection

Riverain Medical, an industry leader and innovator in computer-aided detection (CAD) and advanced visualization technologies, today announced its SoftView Enhanced Chest Imaging and OnGuard Chest X-ray Computer-Aided Detection (CAD) technologies can now integrate In Unison for improved workflow and enhanced lung nodule detection.

30 Nov 2010

More women are dying of lung cancer in UK

New research shows that the rates of lung cancer in women have risen and this could be a sign that efforts to persuade them to quit smoking have failed. The cases among men have fallen on the other hand.

29 Nov 2010

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).

29 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

Jefferson Hospital offers shortest wait times for patients seeking kidney transplant: SRTR

A recent listing of Philadelphia adult kidney transplant programs by The Scientific Registry of Transplant Recipients (SRTR) has listed the transplant program at Thomas Jefferson University Hospital as having the shortest wait times for patients seeking a transplant among programs that have a three-year survival rate of greater than 90 percent.

29 Nov 2010

Whooping cough outbreak in Oklahoma

Oklahoma is witnessing an outbreak of whooping cough with more people falling ill. Health authorities are urging all people over 7 years of age to get vaccinated against the disease.

28 Nov 2010

New WHO report highlights second-hand smoke danger

A report, a first of its kind, that assessed all deaths related to tobacco showed that secondhand smoke sickens millions and kills more than 600,000 people worldwide each year, including more than 165,000 children under 5.

25 Nov 2010